Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer

BACKGROUND: Six months of adjuvant chemotherapy is regarded as the standard of care for patients with stage III colon cancer. However, whether longer treatment can improve prognosis has not been fully investigated. We conducted a phase III study comparing 6 and 12 months of adjuvant capecitabine che...

Descripción completa

Detalles Bibliográficos
Autores principales: Suto, Takeshi, Ishiguro, Megumi, Hamada, Chikuma, Kunieda, Katsuyuki, Masuko, Hiroyuki, Kondo, Ken, Ishida, Hideyuki, Nishimura, Genichi, Sasaki, Kazuaki, Morita, Takayuki, Hazama, Shoichi, Maeda, Koutarou, Mishima, Hideyuki, Ike, Hideyuki, Sadahiro, Sotaro, Sugihara, Kenichi, Okajima, Masazumi, Saji, Shigetoyo, Sakamoto, Junichi, Tomita, Naohiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486458/
https://www.ncbi.nlm.nih.gov/pubmed/28078540
http://dx.doi.org/10.1007/s10147-016-1083-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486458/
https://www.ncbi.nlm.nih.gov/pubmed/28078540
http://dx.doi.org/10.1007/s10147-016-1083-9

Ejemplares similares